BioSpace News Archive

Business

Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020.

January 9, 2020
·
2 min read
Biotech Bay

Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the expansion of its Series A financing with an additional investment of $14.1 million led by Roche Venture Fund and with participation from other investors, bringing the total company financing to more than $50 million to date.

January 9, 2020
·
5 min read
FDA

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors

Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.

January 9, 2020
·
4 min read
FDA

Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor

January 9, 2020
·
14 min read
Business

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

Flexion Therapeutics, Inc. announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2019 and provided initial revenue guidance for 2020.

January 9, 2020
·
6 min read
Business

NeuBase Therapeutics Reports Financial Results for Fiscal Year 2019Expects to report preclinical PK and PD data for the PATrOL™ platform and PATrOL-enabled candidates beginning in Q1 and in Q2 of calendar year 2020

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies using its scalable PATrOL™ platform to address genetic diseases, today reported its financial results for the fiscal year ended September 30, 2019.

January 9, 2020
·
9 min read
Business

Neural Analytics Appoints Diane M. Bryant as Chairman and CEO

Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announced it has appointed former Google Cloud COO Diane M. Bryant as Chairman and CEO, effective immediately.

January 9, 2020
·
3 min read
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will participate in the upcoming 38th Annual J.P. Morgan Healthcare Conference.

January 9, 2020
·
4 min read
BioCapital

Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference

Novavax, Inc. announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference.

January 9, 2020
·
1 min read
Deals

Matinas BioPharma Announces Proposed Public Offering of Common Stock - Jan. 09, 2020

Matinas BioPharma Holdings, Inc. announced that it has commenced an underwritten public offering of its common stock.

January 9, 2020
·
4 min read